Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Amortization (2016 - 2025)

Historic Amortization for Dr Reddys Laboratories (RDY) over the last 14 years, with Q3 2025 value amounting to $1.2 billion.

  • Dr Reddys Laboratories' Amortization rose 519.58% to $1.2 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 519.58%. This contributed to the annual value of $1.1 billion for FY2025, which is 15658.64% up from last year.
  • As of Q3 2025, Dr Reddys Laboratories' Amortization stood at $1.2 billion, which was up 519.58% from $1.1 billion recorded in Q1 2025.
  • Over the past 5 years, Dr Reddys Laboratories' Amortization peaked at $1.2 billion during Q3 2025, and registered a low of $271.5 million during Q1 2022.
  • Over the past 5 years, Dr Reddys Laboratories' median Amortization value was $442.7 million (recorded in 2021), while the average stood at $608.1 million.
  • Per our database at Business Quant, Dr Reddys Laboratories' Amortization crashed by 4447.61% in 2022 and then soared by 28355.99% in 2024.
  • Quarter analysis of 5 years shows Dr Reddys Laboratories' Amortization stood at $440.4 million in 2021, then decreased by 9.55% to $398.3 million in 2022, then decreased by 28.01% to $286.7 million in 2023, then soared by 283.56% to $1.1 billion in 2024, then rose by 5.2% to $1.2 billion in 2025.
  • Its Amortization was $1.2 billion in Q3 2025, compared to $1.1 billion in Q1 2025 and $1.1 billion in Q3 2024.